Clinical effects of discontinuing 5-alpha reductase inhibitor in patients with benign prostatic hyperplasia

Korean Journal of Urology

Volumn 55, Issue 1, 2014, Pages 52-56

  Kim, Won ^a   Jung, Jae Hung ^a   Kang, Tae Wook ^a   Song, Jae Mann ^a   Chung, Hyun Chul ^a  

^a Yonsei University Wonju College of Medicine   (South Korea)

Author keywords

5 Alpha reductase inhibitors; Prostate specific antigen; Prostatic hyperplasia

Indexed keywords

DUTASTERIDE; PROSTATE SPECIFIC ANTIGEN; TAMSULOSIN;

AGED; ARTICLE; DRUG WITHDRAWAL; EJACULATION DISORDER; ERECTILE DYSFUNCTION; GYNECOMASTIA; HUMAN; LIBIDO DISORDER; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; PROSTATE HYPERTROPHY; PROSTATE VOLUME; QUALITY OF LIFE; RETROSPECTIVE STUDY; SCORING SYSTEM; TRANSRECTAL ULTRASONOGRAPHY;

EID: 84892868457     PISSN: 20056737     EISSN: 20056745     Source Type: Journal    
DOI: 10.4111/kju.2014.55.1.52     Document Type: Article

References (24)

1. Emberton M, Andriole GL, de la Rosette J, Djavan B, Hoefner K, Vela Navarrete R, et al. Benign prostatic hyperplasia: a progressive disease of aging men. Urology 2003;61:267-73.
2. Jacobsen SJ, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997;158:481-7.
3. Boyle P, Roehrborn C, Harkaway R, Logie J, de la Rosette J, Emberton M. 5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery. Eur Urol 2004;45:620-6.
4. Debruyne F, Barkin J, van Erps P, Reis M, Tammela TL, Roehrborn C, et al. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 2004;46: 488-94.
5. Marks LS, Andriole GL, Fitzpatrick JM, Schulman CC, Roehrborn CG. The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations. J Urol 2006;176:868-74.
6. Madersbacher S, Marszalek M, Lackner J, Berger P, Schatzl G. The long-term outcome of medical therapy for BPH. Eur Urol 2007;51:1522-33.
7. Roehrborn CG. 5-Alpha-reductase inhibitors prevent the progression of benign prostatic hyperplasia. Rev Urol 2003;5 Suppl 4:S18-27.
8. Tanguay S, Awde M, Brock G, Casey R, Kozak J, Lee J, et al. Diagnosis and management of benign prostatic hyperplasia in primary care. Can Urol Assoc J 2009;3(3 Suppl 2):S92-100.
9. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G; ARIA3001 ARIA3002 and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60:434-41.
10. Marberger M, Harkaway R, de la Rosette J. Optimising the medical management of benign prostatic hyperplasia. Eur Urol 2004;45:411-9.
11. Nickel JC, Barkin J, Koch C, Dupont C, Elhilali M. Finasteride monotherapy maintains stable lower urinary tract symptoms in men with benign prostatic hyperplasia following cessation of alpha blockers. Can Urol Assoc J 2008;2:16-21.
12. Roehrborn CG, Lukkarinen O, Mark S, Siami P, Ramsdell J, Zinner N. Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies. BJU Int 2005;96: 572-7.
13. Kirby RS, Roehrborn C, Boyle P, Bartsch G, Jardin A, Cary MM, et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003;61:119-26.
14. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387-98
15. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab 2004;89: 2179-84.
16. Barkin J, Guimaraes M, Jacobi G, Pushkar D, Taylor S, van Vierssen Trip OB. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur Urol 2003;44: 461-6.
17. Andersen JT, Nickel JC, Marshall VR, Schulman CC, Boyle P. Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. Urology 1997;49:839-45.
18. Kaplan SA, Ghafar MA, Volpe MA, Lam JS, Fromer D, Te AE. PSA response to finasteride challenge in men with a serum PSA greater than 4 ng/ml and previous negative prostate biopsy: preliminary study. Urology 2002;60:464-8.
19. Stoner E. The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group. J Urol 1992;147:1298-302.
20. Jeong YB, Kwon KS, Kim SD, Kim HJ. Effect of discontinuation of 5alpha-reductase inhibitors on prostate volume and symptoms in men with BPH: a prospective study. Urology 2009;73:802-6.
21. Andriole GL, Marberger M, Roehrborn CG. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride. J Urol 2006;175:1657-62.
22. Bartsch G, Fitzpatrick JM, Schalken JA, Isaacs J, Nordling J, Roehrborn CG. Consensus statement: the role of prostate-specific antigen in managing the patient with benign prostatic hyperplasia. BJU Int 2004;93 Suppl 1:27-9.
23. Guess HA, Gormley GJ, Stoner E, Oesterling JE. The effect of finasteride on prostate specific antigen: review of available data. J Urol 1996;155:3-9.
24. Andriole GL, Bostwick D, Brawley OW, Gomella L, Marberger M, Montorsi F, et al. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study. J Urol 2011;185:126-31.